Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells

International Journal of Oncology

Volumn 29, Issue 1, 2006, Pages 237-247

  Iacopino, Fortunata ^a   Lama, Gina ^a   Angelucci, Cristiana ^a   Sica, Gigliola ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Dihydrotestosterone; Epidermal growth factor; ERK activity; GnRH agonist; Prostate cancer cell proliferation

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANDROSTANOLONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LEUPRORELIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE INHIBITOR; TYRPHOSTIN;

ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; HUMAN; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; HUMANS; LEUPROLIDE; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TYRPHOSTINS;

EID: 36048989280     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.1.237     Document Type: Article

References (39)

1. Shalev E and Leung PC: Gonadotropin-releasing hormone and reproductive medicine. J Obstet Gynaecol Can 25: 98-113, 2003.
2. Florio S, Pagnini U, Crispino A, Pacilio C, Crispino L and Giordano A: GnRH and steroids in cancer. Front Biosci 7: d1590-d1608, 2002.
3. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL and Halmos G: Hypothalamic hormones and cancer. Front Neuroendocrinol 22: 248-291, 2001.
4. Sica G, Iacopino F, Settesoldi D and Zelano G: Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells. Eur Urol 35 (suppl 1): 2-8, 1999.
5. Sica G, Zelano G, Settesoldi D and Iacopino F: Regulation of prostate-specific antigen gene expression by an LH-RH analogue in human prostatic cells. Anticancer Res 23: 1283-1287, 2003.
6. Angelucci C, Iacopino F, Lama G, Capucci S, Zelano G, Boca M, Pistilli A and Sica G: Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells. Anticancer Res 24: 2729-2738, 2004.
7. Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12: 9-18, 2002.
8. Hunter T: Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signalling. Cell 80: 225-236, 1995.
9. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA and Marcelli M: Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64: 7156-7168, 2004.
10. Guo C, Luttrell LM and Price DT: Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 163: 1027-1032, 2000.
11. Moretti RM, Montagnani Marelli M, Dondi D, Poletti A, Martini L, Motta M and Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81: 3930-3937, 1996.
12. Eaton CL, Davies P, Harper M, France T, Rushmere N and Griffiths K: Steroids and the prostate. J Steroid Biochem Mol Biol 40: 175-183, 1991.
13. Peterson GL: A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83: 346-356, 1977.
14. Sasaki H, Nio M, Iwami D, Funaki N, Ohi R and Sasano H: Cytokeratin subtypes in biliary atresia: immunohistochemical study. Pathol Int 51: 511-518, 2001.
15. Jones HE, Barrow D, Dutkowski CM, Goddard L, Smith C, Harper ME and Nicholson RI: Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways. Prostate 49: 38-47, 2001.
16. Hobisch A, Fiechtl M, Sandahl-Sorensen B, Godoy-Tundidor S, Artner-Dworzak E, Ramoner R, Bartsch G and Culig Z: Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression. Prostate 59: 401-408, 2004. (Pubitemid 38661807)
17. Desruisseau S, Ghazarossian-Ragni E, Chinot O and Martin PM: Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic-cancer cell lines. Int J Cancer 66: 796-801, 1996. (Pubitemid 26197949)
18. Jones HE, Eaton CL, Barrow D, Dutkowski CM, Gee JM and Griffiths K: Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 30: 219-231, 1997. (Pubitemid 27172833)
19. Kue PF and Daaka Y: Essential role for G proteins in prostate cancer cell growth and signaling. J Urol 164: 2162-2167, 2000.
20. Jarrard DF, Blitz BF, Smith RC, Patai BL and Rukstalis DB: Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 24: 46-53, 1994.
21. Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE and Nicholson RI: New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145. Int J Cancer 71: 1010-1018, 1997.
22. Motta M, Dondi D, Moretti RM, Montagnani Marelli M, Pimpinelli F, Maggi R and Limonta P: Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. J Steroid Biochem Mol Biol 56 (1-6 Spec No): 107-111, 1996.
23. Emons G, Muller V, Ortmann O and Schulz KD: Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 65: 199-206, 1998.
24. Chen T, Cho RW, Stork PJ and Weber MJ: Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 59: 213-218, 1999. (Pubitemid 29062980)
25. Peterziel H, Mink S, Schonert A, Becker M, Klocker H and Cato AC: Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 18: 6322-6329, 1999.
26. Xiao D and Singh SV: Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 62: 3615-3619, 2002.
27. Bakin RE, Gioeli D, Sikes RA, Bissonette EA and Weber MJ: Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63: 1981-1989, 2003.
28. Gutierrez-Canas I, Juarranz MG, Collado B, Rodriguez-Henche N, Chiloeches A, Prieto JC and Carmena MJ: Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate 63: 44-55, 2005.
29. Yano S, Macleod RJ, Chattopadhyay N, Tfelt-Hansen J, Kifor O, Butters RR and Brown EM: Calcium-sensing receptor activation stimulates parathyroid hormone-related protein secretion in prostate cancer cells: role of epidermal growth factor receptor transactivation. Bone 35: 664-672, 2004.
30. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr and Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284, 1999.
31. Bell WC, Myers RB, Hosein TO, Oelschlager DK and Grizzle WE: The response of extracellular signal-regulated kinase (ERK) to androgen-induced proliferation in the androgen-sensitive prostate cancer cell line, LNCaP. Biotech Histochem 78: 11-16, 2003.
32. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C and Auricchio F: Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19: 5406-5417, 2000.
33. Price DT, Della Rocca G, Guo C, Ballo MS, Schwinn DA and Luttrell LM: Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 162: 1537-1542, 1999. (Pubitemid 29428632)
34. Reiss N, Llevi LN, Shacham S, Harris D, Seger R and Naor Z: Mechanism of mitogen-activated protein kinase activation by gonadotropin-releasing hormone in the pituitary of alphaT3-1 cell line: differential roles of calcium and protein kinase C. Endocrinology 138: 1673-1682, 1997. (Pubitemid 27137121)
35. Kraus S, Levy G, Hanoch T, Naor Z and Seger R: Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 64: 5736-5744, 2004.
36. Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N and Murata Y: Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res 59: 5133-5142, 1999. (Pubitemid 29503973)
37. Yeh PY, Chuang SE, Yeh KH, Song YC, Chang LL and Cheng AL: Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 23: 3580-3588, 2004.
38. Recio JA, Paez JG, Maskeri B, Loveland M, Velasco JA and Notario V: Both normal and transforming PCPH proteins have guanosine diphosphatase activity but only the oncoprotein cooperates with Ras in activating extracellular signal-regulated kinase ERK1. Cancer Res 60: 1720-1728, 2000.
39. Marchetti A, Cecchinelli B, D'Angelo M, D'Orazi G, Crescenzi M, Sacchi A and Soddu S: p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. Cell Death Differ 11: 596-607, 2004.